MAP2K7 and melanoma: Besides the IMspire150 trial, the keynote-022 and COMBI-I trials did not demonstrate that compared with targeted drugs, PD-(L)1 monoclonal antibody combined with BRAF and MEK inhibitors increased the PFS in BRAF mutation-positive advanced melanoma patients [87–89].